Physician profile
Chloe Kidd
NPI 1508546979
$1,341.08
in general payments reported to CMS, 2019-2025
17 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $176 · 2024: $1,050 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $192.14 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $183.76 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $169.83 | 2023-2025 | |
| Pfizer INC. | $146.52 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $137.35 | 2024 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $87.20 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $71.93 | 2023-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.80 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $62.49 | 2024 | |
| Corcept Therapeutics | $46.96 | 2024 | Korlym |
| Amgen INC. | $41.66 | 2024 | Evenity, Prolia |
| Idorsia Pharmaceuticals US INC | $35.52 | 2023-2024 | Quviviq |
| Astellas Pharma US INC | $24.69 | 2024 | Veozah |
| Exact Sciences Corporation | $21.91 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.01 | 2023 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.82 | 2024 | Rexulti |
| Abbott Laboratories | $14.49 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.